BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6274970)

  • 1. In vitro susceptibility of antimony-resistant Leishmania to alternative drugs.
    Berman JD
    J Infect Dis; 1982 Feb; 145(2):279. PubMed ID: 6274970
    [No Abstract]   [Full Text] [Related]  

  • 2. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis.
    Berman JD; Wyler DJ
    J Infect Dis; 1980 Jul; 142(1):83-6. PubMed ID: 6249874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous leishmaniasis.
    Bryceson A
    Br J Dermatol; 1976 Feb; 94(2):223-6. PubMed ID: 1252353
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphorylation and anti-leishmanial activity of formycin B.
    Carson DA; Chang KP
    Biochem Biophys Res Commun; 1981 Jun; 100(3):1377-83. PubMed ID: 7271805
    [No Abstract]   [Full Text] [Related]  

  • 5. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar.
    Wali JP; Aggarwal P; Gupta U; Saluja S; Singh S
    J Infect Dis; 1992 Jul; 166(1):215-6. PubMed ID: 1607703
    [No Abstract]   [Full Text] [Related]  

  • 6. American Leishmania spp: formycin B treatment of cutaneous leishmaniasis in mice.
    Rojas T; Avila JL
    Parasitology; 1987 Jun; 94 ( Pt 3)():467-74. PubMed ID: 3614989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B in visceral leishmaniasis.
    Jha BB
    Indian Pediatr; 1996 Nov; 33(11):971. PubMed ID: 9141838
    [No Abstract]   [Full Text] [Related]  

  • 8. Late cutaneous leishmaniasis.
    Hart M; Livingood CS; Goltz RW; Totonchy M
    Arch Dermatol; 1969 Apr; 99(4):455-8. PubMed ID: 5769330
    [No Abstract]   [Full Text] [Related]  

  • 9. [The therapy of cutaneous and mucocutaneous leishmaniasis].
    Blum J; Hatz C; Junghanss T
    Dtsch Med Wochenschr; 1994 Aug; 119(34-35):1169-72. PubMed ID: 8076505
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
    Mishra M
    J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286
    [No Abstract]   [Full Text] [Related]  

  • 12. Leishmania donovani: oral efficacy and toxicity of formycin B in the infected hamster.
    Berman JD; Keenan CM; Lamb SR; Hanson WL; Waits VB
    Exp Parasitol; 1983 Oct; 56(2):215-21. PubMed ID: 6617804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and mechanism of action of formycin B in Leishmania.
    Rainey P; Santi DV
    Proc Natl Acad Sci U S A; 1983 Jan; 80(1):288-92. PubMed ID: 6572004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and new discoveries in the treatment of leishmaniasis.
    Singh S; Sivakumar R
    J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of kala-azar].
    Neves J
    Rev Paul Med; 1983; 101(6):237-9. PubMed ID: 6677985
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of localized cutaneous leishmaniasis].
    Buffet P; Caumes E; Gentilini M
    Ann Dermatol Venereol; 1994; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
    Morizot G; Jouffroy R; Faye A; Chabert P; Belhouari K; Calin R; Charlier C; Miailhes P; Siriez JY; Mouri O; Yera H; Gilquin J; Tubiana R; Lanternier F; Mamzer MF; Legendre C; Peyramond D; Caumes E; Lortholary O; Buffet P
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004304. PubMed ID: 26735920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of nicotinamide/antileishmanial drug combinations.
    Gazanion E; Vergnes B; Seveno M; Garcia D; Oury B; Ait-Oudhia K; Ouaissi A; Sereno D
    Parasitol Int; 2011 Jan; 60(1):19-24. PubMed ID: 20884376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B for visceral leishmaniasis resistant to pentavalent antimonial drugs in AIDS.
    Rodilla F; Magraner J; Aznar J; Orovitg F; Alcácer F; Colomina J; Ferriols F
    Ann Pharmacother; 1994 Nov; 28(11):1305. PubMed ID: 7849352
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous leishmaniasis [proceedings].
    Smit AM; van der Kaay HJ
    Dermatologica; 1977; 154(1):56-7. PubMed ID: 191304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.